A$0.06 -0.0 -3.2%
Last Trade - 25/02/20
| Market Cap | ÂŁ92.8m |
| Enterprise Value | ÂŁ89.7m |
| Revenue | ÂŁ0.128k |
| Position in Universe | 535th / 1834 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
PYC Therapeutics Limited, formerly Phylogica Limited, is a pharmaceutical company. The Company is engaged combining its cell-penetrating peptides (CPP) technology with in ASOs to create a pipeline of drugs called CPP-ASOs. The Company intends to expand its pipeline to include other disease indications and therapeutic areas such as genetic neurodegenerative and liver diseases. Its pipeline products is Ocular, which is focused on treating retinitis pigmentosa and inherited retinal disease.
| Last Annual | June 30th, 2019 |
| Last Interim | June 30th, 2019 |
| Incorporated | October 9, 2001 |
| Public Since | March 30, 2005 |
| No. of Shareholders: | n/a |
| No. of Employees: | 23 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 2,931,427,990 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Harry Perkins Institute 6 Verdun St, NEDLANDS, 6009, Australia |
| Web | https://pyctx.com/ |
| Phone | +61 8 61510992 |
| Contact | Rudi Michelson (IR Contact Officer) |
| Auditors | HLB Mann Judd |
